Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEE: Pembrolizumab + Chemotherapy vs Pembrolizumab in PD-L1 High NSCLC
NCT04547504Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Centre Hospitalier Universitaire de Brest. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04547504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547504.